GMZ-1 is a podophyllotoxin derivative that suppresses growth and induces apoptosis in adriamycin-resistant K562/A02 cells through modulation of MDR1 expression

Cao,Bo; Yang,Shuwang; Li,Wuwei; Chen,Hong; Chen,Yaze; Liu,Yongfeng; Liu,Bin

doi:10.3892/mmr.2017.7862

GMZ-1 is a podophyllotoxin derivative that suppresses growth and induces apoptosis in adriamycin-resistant K562/A02 cells through modulation of MDR1 expression

Authors:
- Bo Cao
- Shuwang Yang
- Wuwei Li
- Hong Chen
- Yaze Chen
- Yongfeng Liu
- Bin Liu
View Affiliations

Affiliations: Department of Pharmacognosy, Logistics University of Chinese People's Armed Police Forces, Tianjin 300309, P.R. China, Department of Pharmacology, School of Basic Medicine, Tianjin Medical University, Tianjin 300070, P.R. China, Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Tianjin 300162, P.R. China
Published online on: October 25, 2017 https://doi.org/10.3892/mmr.2017.7862
Pages: 474-478

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of multidrug resistance (MDR) during cancer chemotherapy is a major challenge for treatment. With the aim of identifying drugs that are capable of targeting treatment‑resistant cancer cells, the present study evaluated the efficacy of GMZ‑1 in cancer chemotherapy using K562/A02, an MDR leukemia cell line. Cell viability and apoptosis were measured by MTT assay and flow cytometry/Giemsa staining, respectively. The expression levels of the MDR protein 1 (MDR1) gene transcript and protein in K562/A02 cells were determined by reverse transcription‑quantitative polymerase chain reaction and western blot analyses, respectively. GMZ‑1 suppressed the viability of various human cancer cell lines and induced apoptosis in the K562/A02 cell line in a time‑ and concentration‑dependent manner. GMZ‑1 toxicity may be associated with a decrease in MDR gene expression. These findings demonstrated that GMZ‑1 may have efficacy as a potential antitumor drug to overcome leukemia cell resistance to apoptosis induced by chemotherapy.

View Figures

View References

1	Yang CZ, Luan FJ, Xiong DS, Liu BR, Xu YF and Gu KS: Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin. Zhongguo Yao Li Xue Bao. 16:333–337. 1995.PubMed/NCBI
2	Hackl H, Astanina K and Wieser R: Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol. 10:512017. View Article : Google Scholar : PubMed/NCBI
3	Dalton WS: Mechanisms of drug resistance in hematologic malignancies. Semin Hematol. 34 4 Suppl 5:S3–S8. 1997.
4	Young AM, Allen CE and Audus KL: Efflux transporters of the human placenta. Adv Drug Deliv Rev. 55:125–132. 2003. View Article : Google Scholar : PubMed/NCBI
5	Lee SY, Rhee YH, Jeong SJ, Lee HJ, Lee HJ, Jung MH and Kim SH, Lee EO, Ahn KS, Ahn KS and Kim SH: Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol. 26:424–431. 2011. View Article : Google Scholar : PubMed/NCBI
6	Dönmez Y, Akhmetova L, Iseri ÖD, Kars MD and Gündüz U: Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother Pharmacol. 67:823–828. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wibowo M, Levrier C, Sadowski MC, Nelson CC, Wang Q, Holst J, Healy PC, Hofmann A and Davis RA: Bioactive dihydro-β-agarofuran sesquiterpenoids from the Australian rainforest plant Maytenus bilocularis. J Nat Prod. 79:1445–1453. 2016. View Article : Google Scholar : PubMed/NCBI
8	Pajeva I and Wiese M: Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study. J Med Chem. 41:1815–1826. 1998. View Article : Google Scholar : PubMed/NCBI
9	Schondörf T, Kurbacher CM, Göhring UJ, Benz C, Becker M, Sartorius J, Kolhagen H, Mallman P and Neumann R: Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res. 22:2199–2203. 2002.PubMed/NCBI
10	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
11	Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV and Limtrakul PN: Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol. 64:573–582. 2002. View Article : Google Scholar : PubMed/NCBI
12	Yu ST, Chen TM, Tseng SY and Chen YH: Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun. 358:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
13	Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K and Sugimoto Y: Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci. 97:1198–1204. 2006. View Article : Google Scholar : PubMed/NCBI
14	Zhou YG, Li KY and Li HD: Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells. Eur J Clin Pharmacol. 64:697–703. 2008. View Article : Google Scholar : PubMed/NCBI
15	Baldwin EL and Osheroff N: Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents. 5:363–372. 2005. View Article : Google Scholar : PubMed/NCBI
16	Hande KR: Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 34:1514–1521. 1998. View Article : Google Scholar : PubMed/NCBI
17	Kobayashi K and Ratain MJ: Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother Pharmacol. 34 Suppl:S64–S68. 1994. View Article : Google Scholar : PubMed/NCBI
18	Smith MA, Rubinstein L, Anderson JR, Arthur D, Catalano PJ, Freidlin B, Heyn R, Khayat A, Krailo M, Land VJ, et al: Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 17:569–577. 1999. View Article : Google Scholar : PubMed/NCBI
19	Choudhury RC, Palo AK and Sahu P: Cytogenetic risk assessment of etoposide from mouse bone marrow. J Appl Toxicol. 24:115–122. 2004. View Article : Google Scholar : PubMed/NCBI
20	Attia SM, Al-Anteet AA, Al-Rasheed NM, Alhaider AA and Al-Harbi MM: Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane. Cancer Chemother Pharmacol. 64:837–845. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kapiszewska M, Cierniak A, Papiez MA, Pietrzycka A, Stepniewski M and Lomnicki A: Prolonged quercetin administration diminishes the etoposide-induced DNA damage in bone marrow cells of rats. Drug Chem Toxicol. 30:67–81. 2007. View Article : Google Scholar : PubMed/NCBI
22	Enomoto R, Koshiba C, Suzuki C and Lee E: Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects. Cancer Chemother Pharmacol. 67:1063–1072. 2011. View Article : Google Scholar : PubMed/NCBI